CMMB CMMB
Company Profile ↓Company Overview
CMMB (CMMB) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 14.5.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -56.25% |
| 6 Months: | +8.02% |
| 3 Months: | +7.36% |
| 1 Month: | -36.82% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)56.93 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 56.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -9.91M | -4.44M | -7.17M | -1.70M | -1.08M | -1.22M | -1.70M | -2.77M | -2.97M | -5.10M | -6.19M | -8.08M | -8.75M |
| Diluted EPS | - | - | - | - | - | - | - | 0.01 | 0.01 | 0.02 | 0.03 | 0.04 | 0.04 |
| R&D Expense | 4.13M | 2.58M | 5.57M | 1.55M | 847.00K | 1.03M | 1.16M | 1.31M | 1.49M | 2.75M | 2.91M | 5.42M | 6.89M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 |
|---|---|---|---|---|---|
| Net Income | -13.80M | -27.12M | -5.95M | -12.48M | -27.65M |
| Diluted EPS | - | - | - | 0.06 | 0.12 |
| R&D Expense | 7.51M | 13.30M | 4.68M | 6.33M | 16.98M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 |
|---|---|---|---|---|---|---|
| Total Assets | - | 12.76M | 19.75M | 12.48M | 64.35M | 43.06M |
| Total Equity | -609.00K | 9.80M | 12.37M | 10.80M | 61.47M | 36.22M |
| Cash & Equivalents | - | 7.52M | 17.57M | 11.67M | 15.19M | 13.52M |
| Total Liabilities | - | 2.96M | 4.85M | 1.67M | 2.89M | 6.84M |
| Current Liabilities | - | 2.75M | 4.12M | 1.32M | 2.65M | 6.75M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -14.22M | -16.46M | -5.24M | -12.37M | -20.37M |
| Investing Cash Flow | -213.00K | -95.00K | -62.00K | -45.19M | 19.53M |
| Financing Cash Flow | 20.62M | 26.62M | 4.75M | 61.07M | -808.00K |
| Capital Expenditure | -213.00K | -95.00K | -38.00K | -239.00K | -68.00K |
| Free Cash Flow | -14.44M | -16.55M | -5.28M | -12.61M | -20.44M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | -140.7% | -219.2% | -55.1% | -20.3% | -76.3% |
| ROCE % | - | - | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CMMB
Chemomab, Scipher tie merger to AI-guided rheumatoid arthritis trial - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOVFRoR3o1UzVNVjQzakkxOTNrSzRzWGIyandNMFhMV0VZelV3TURTbEllTjAtZkcwSW9ZMXd1ZDhIZms3N25XbDVfVGtaeVhJbExINmxFczNpTWhZdjkxdThGc3JIS2o2SzdsbHBjbDVOOTZtdWpLV0w0VEVXaWlDdnJLYmRScWNWUXFuOW…
Insider Purchase: Chief Executive Officer of $CMMB Buys 4,926 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOV3ZsUlZpa0hwM3RxaEx1UWZyUGdFUVhyaUVnaTRnVUhPM2c5SlIyT2VWaHlzc1NXQTI3a0FuMlF6ZFVnclpwWWJoQk1VZk1CMFQ5ajRGaHI0OHdIMVE2eHAySlE4dFZ3Nm9lb0c0QWIyTGl2aVdTYVFKSkktalNJQ3o1TVBkdXlCRVJZTn…
Chemomab Therapeutics Ltd. Revenue Breakdown – NASDAQ:CMMB - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE1TX2Q0UFpveXdvb0JKdHJPeFhDZzBqUnBIVUNnUXRFaGQ1NFgxUU5uY3E4VkJkMGhyNGNXbUNKd1VHUkhxUjMxOFhlNlBKZUdNclUwMW1MVVc2azJZY3hZZ0Y0QVNBdzJveFZVLVpvOElWMm1FOXlB?oc=5" target="_blank">Chemoma…
Chemomab Therapeutics Ltd. (CMMB) Chemomab Therapeutics Ltd., - M&A Call - Slideshow - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxON2VZNjJJUDBFWUJWQlNkSE12a2RXbnYxNjBhNmxtVnAwVDhHbTRfaGlZTHRZOElDWXRockJwRVBiZXE4SUtDRnFpUEpZeE1kWGVWcG03R3NHN2dMQlJFTWtsR2NwREFyVUxLWENmeTBsMTQtNFdJZWtWeVkyRjVZMlhFWVRFdGk3YzZuOD…
On Thursday, there are stocks with unusual volume. Let's take a look. - ChartMill
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPM3A5Z1NDcTA4LTBDbXRBRmk5SF9yVnA1Qmd6MW9zSWQzSFF4S3lGZUxaaGhyRmxPRnZvQUEwV3pnbWItd1B3T1hXbFNzRE5hRHdWQ1VydmZHM3phSmVGV09RSDJTRGVtU1JMSzIxcTcwRUY5a0hKSDRqSXVYX09oRTBBU2w5aHJvX1RjRn…
Top Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch - rttnews.com
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPWDdCMWdkclNhVGUxeHphMzl6YWpVNlQ1d2RjRU1QaU90TTNodzlMa0NhYTJrZFNlLXpsbU9Jc2xaa0NTVDJVM1NUVHA1RVp3Wmk5UUF1QVZqSTVIWlpCUkVhanBHbjBMSG96QVBVY2lCUU5Vb2NWMm9RVzBzWDAtVmZoZlZXbFZWNHBic2…
CMMB — Frequently Asked Questions
What is the current share price of CMMB?
As of 2026-08-05 17:25 PDT, CMMB trades at $1.75 on NASDAQ/NYSE. Its 52-week range is $1.36 to $4.00.
What is the P/E ratio of CMMB?
CMMB trades at a trailing price-to-earnings (P/E) ratio of 14.46.
What is the return on equity (ROE) of CMMB?
CMMB has a return on equity (ROE) of -76.32%.
Is CMMB a good stock to buy?
This page provides a data-driven analysis of CMMB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.